Amalgam Rx announced today that it expanded its global agreement with Novo Nordisk over the commercialization of Dose Check. Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin. The two companies partnered to incorporate and integrate […]
Novo Nordisk
Abbott FreeStyle LibreLink app now pairs with Novo Nordisk insulin pens in UK
![The NovoPen Echo smart insulin pen now works with Dexcom CGM. [Image from Novo Nordisk]](https://www.drugdeliverybusiness.com/wp-content/uploads/2022/11/Novo-Nordisk-NovoPen-Echo-Smart-Insulin-Pen-Abbott-150x86.jpg)
Novo Nordisk (NYSE:NVO) announced that users of the Abbott (NYSE:ABT) FreeStyle LibreLink app can connect to its smart insulin pens. People living with diabetes in the United Kingdom can connect the app to the Novo Nordisk smart, connected pens. Users of the Abbott FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology can see a […]
WHO delivers insulin pens to Ukraine hospitals with support from Novo Nordisk
The World Health Organization (WHO) announced that it delivered more than 26 metric tonnes of insulin pens to Ukraine. WHO distributed approximately 57,320 pounds of insulin pens (more than 370,000 total pens) to hospitals throughout Ukraine. It represents part of an effort to help those with diabetes in the country during the ongoing humanitarian crisis. […]
EMA gives positive opinion on Novo Nordisk’s human insulin with flexible storage
Novo Nordisk (NYSE:NVO) announced that the European Medicines Agency (EMA) granted a positive opinion on a storage update for insulin. EMA’s positive opinion relates to a proposed update to the storage conditions of two human insulins: Actrapid (short-acting insulin) and Insulatard (intermediate-acting insulin). Bagsværd, Denmark-based Novo Nordisk said in a news release that the EMA’s […]
Novo Nordisk completes acquisition of Dicerna Pharmaceuticals
Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. […]
Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires
Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired. The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on […]
Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes
The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms. To accelerate efforts to mine genetic data for insights into mechanisms — and eventually rationally design treatments — the trio of entities launched the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease based […]
Walmart teams up with Novo Nordisk to launch private-brand analog insulin
Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin. Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The […]
FDA classifies Novo Nordisk insulin pen recalls as Class I
In May, Novo Nordisk announced that it voluntarily recalled 1,468 product samples related to its Levemir, Tresiba, Fiasp, Novolog and Xultophy insulin lines. The products were held at sub-freezing temperatures, prompting the FDA to recently classify the recalls as Class I. FDA uses the Class I designation for situations where there is “a reasonable probability” […]
Bigfoot Biomedical wins FDA clearance for smart insulin pen cap system
Bigfoot Biomedical announced today that it received FDA 510(k) clearance for its Bigfoot Unity diabetes management system. Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release. Bigfoot Unity smart pen caps offer on-demand […]
